Biologics/Immunotherapy News

James M. Tracy, DO, clinical professor of pediatrics at University of Nebraska College of Medicine, is set to become the president of the American College of Allergy, Asthma & Immunology ahead of its conference, Oct. 24-28, in Boston.

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster presented at the CHEST Annual Meeting.

BOSTON — Patients aged 65 years and older on dupilumab for asthma and chronic rhinosinusitis experienced greater risks for adverse events than younger patients, according to a poster presented at the CHEST Annual Meeting.

BOSTON — Physicians should consider delayed hypersensitivity reactions such as serum sickness when patients experience symptoms during biologic treatment, according to a poster presented at the CHEST Annual Meeting.

The American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting will take place in Boston this year under the theme “Advancing Allergy/Immunology Discovery.”

Deucrictibant was well tolerated in daily 40 mg doses and showed no new safety signals among patients with hereditary angioedema, according to a poster presented at Bradykinin Symposium 2024 in Berlin.

Patients with severe asthma and small airways disease did not respond as well to omalizumab treatment, according to a poster presented at the European Respiratory Society International Congress.

Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in Pediatric Allergy and Immunology.

Adolescents with hereditary angioedema experienced fewer attacks, improved quality of life and treatment satisfaction with lanadelumab, according to a study published in Annals of Allergy, Asthma & Immunology.

Regeneron Pharmaceuticals Inc. and Sanofi announced the FDA approval of dupilumab for adolescents aged 12 to 17 years with chronic rhinosinusitis with nasal polyps.